Medical device company from Tel Aviv that offers a breakthrough technology enabling clinicians to personalize pain control and avoid overmedication.

Medasense’s flagship product, the PMD-200™ with its NOL® index, is a unique platform that objectively monitors and quantifies the patient’s pain response by means of a proprietary non-invasive sensor platform and artificial intelligence. Clinical studies have demonstrated its impact on patient safety and outcomes, including opioid sparing, less postoperative pain experienced by patients in the post anesthesia care unit, and reduced cost of care.